Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021Show others and affiliations
2023 (English)In: Maturitas, ISSN 0378-5122, E-ISSN 1873-4111, Vol. 175, article id 107787Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: To describe the trends in the prevalence of use menopausal hormone therapy (MHT) in Sweden over the period 2000-2021 and to analyse the impact of different lengths of run-in on the calculated incident use. STUDY DESIGN: Individual-level data on MHT dispensations for 2.5 million women aged 45-69 years for the period 2006-2021 were analysed. Aggregated sales volumes in defined daily dose (DDD) were available for the whole study period (2000-2021).
MAIN OUTCOME MEASURES: One-year prevalence and one-year incidence (18-month run-in) per 1000 women and DDD per 1000 women per day of MHT were the main outcome measures. The predictive values for incidence representing first-ever use of MHT were calculated for different run-in periods, which is a defined period without dispensations.
RESULTS: Both the DDD, from 2000, and the prevalence, from 2006, decreased by over 80 % in women aged 50-54 years, until 2010, when the use of MHT stabilised. The predictive value for incident users to be first-ever users was 88 % in women aged 50-54 years, with a run-in of 18 months, in 2021. The incidence was stable between 2007 and 2016. From 2017 the incidence increased, being most pronounced for women close to menopause.
CONCLUSIONS: MHT use decreased significantly after the turn of the century, but has increased since 2017. A run-in period of 18 months was found suitable and reliable for defining incident users of MHT in the age intervals closest to menopause. Incidence seems to be a more sensitive measure than prevalence or DDD for the early detection of changes in trends in prescriptions of MHT.
Place, publisher, year, edition, pages
Elsevier, 2023. Vol. 175, article id 107787
Keywords [en]
Climacteric, Hormone replacement therapy, Incidence, Menopausal hormone therapy, Pharmacoepidemiology, Run-in period
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
URN: urn:nbn:se:oru:diva-106594DOI: 10.1016/j.maturitas.2023.107787ISI: 001030486100001PubMedID: 37354643Scopus ID: 2-s2.0-85162266765OAI: oai:DiVA.org:oru-106594DiVA, id: diva2:1775830
Note
Funding agencies:
The Medical Research Council of Southeast Sweden FORSS-646401 FORSS-746391
NEPI Foundation - the Swedish Network for Pharmacoepidemiology, Stockholm, Sweden
2023-06-272023-06-272024-01-02Bibliographically approved